{"nctId":"NCT00857454","briefTitle":"A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","startDateStruct":{"date":"2008-10"},"conditions":["Hypogonadism"],"count":71,"armGroups":[{"label":"Testosterone MD-lotion","type":"EXPERIMENTAL","interventionNames":["Drug: Testosterone MD-Lotion"]}],"interventions":[{"name":"Testosterone MD-Lotion","otherNames":["LY900011","Axiron"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hypogonadal males with a qualifying general medical health who have Completed the MTE08 trial up to and including Day 120/121 in a compliant manner\n* Were able to communicate with the trial staff, understand the Trial Information Sheet and sign the Written Informed Consent Forms; were willing to follow the Protocol requirements and comply with Protocol restrictions and procedures\n\nExclusion Criteria:\n\n* Any clinically significant chronic illness or finding and/or laboratory testing that would interfere with the trial objectives or safety of the subject\n* Any man in whom testosterone therapy was contraindicated, which included those with:\n\n  * Known or suspected carcinoma (or history of carcinoma) of the prostate or clinically significant symptoms of benign prostatic hyperplasia and/or clinically significant symptoms of lower urinary obstructions and with a International Prostate Symptoms Score (IPSS) score of greater than or equal to 19\n  * Known or suspected carcinoma (or history of carcinoma) of the breast\n  * Severe liver disease (i.e. cirrhosis, hepatitis or liver tumours or liver function tests \\>2 times the upper limit of the normal range values\n  * Active deep vein thrombosis, thromboembolic disorders or a documented history of these conditions\n  * Current significant cerebrovascular or coronary artery disease\n  * Untreated sleep apnoea\n  * Haematocrit of \\>54%\n  * Untreated moderate to severe depression\n* Men with clinically significant prostate exam or clinically significant elevated serum Prostate Specific Antigen (PSA) level (\\> 4 ng/mL) or age adjusted reference range of PSA values\n* Men taking concomitant medications (prescribed, over-the-counter or complementary) that would affect Sex Hormone Binding Globulin (SHBG) or testosterone concentrations (excluding Testosterone MD-Lotion (cutaneous solution)) or metabolism such as warfarin, insulin, opiates, gonadotropin-releasing hormone analogues (GnRH), 5 alpha reductase inhibitors, propanolol, oxyphenbutazone, corticosteroids (except for physiological replacement doses), estradiol\n* Men with uncontrolled diabetes (Hemoglobin A1c \\[HbA1c\\] greater than or equal to 10%)\n* Subjects intending to have any surgical procedure during the course of the trial\n* Subjects with a partner of child bearing potential who are not willing to use adequate contraception for the duration of the trial\n* Subjects whose partners are pregnant","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline MTE08 to MTE09 Endpoint in Draize Score","description":"Draize score is a measurement of skin irritability of the application site based on erythema/escar and oedema. Erythema/eschar scoring ranges from 0 (no erythema) to 4 (severe erythema \\[beet redness\\] to slight eschar formation \\[injuries in depth\\]). Oedema scoring ranges from 0 (no oedema) to 4 (severe oedema \\[raised more than 1 millimeter and extending beyond area of exposure\\]. The total Draize score ranges from 0 to 8.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Fasting Insulin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"11.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Fasting Glucose","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.25","spread":"35.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Prostatic Specific Antigen (PSA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"3.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.82","spread":"3.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Estradiol","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.76","spread":"18.97"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Hemoglobin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"1.160"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline MTE08 to MTE09 Follow-up in Hematocrit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.04"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":71},"commonTop":["Application site erythema","Back pain","Dry skin","Cardiac flutter","Umbilical hernia"]}}}